• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen

Amgen, Boston Children’s Hospital partner to find genes linked to pain disorders

October 17, 2017 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) announced today that it inked a one-year collaboration with Boston Children’s Hospital to study patients with pain syndromes in an effort to identify potential genetic targets. The collaboration will combine Amgen’s work in genetic target identification and the division of pain medicine at Boston Children’s Hospital. “Traditional approaches to analgesic drug discovery have been […]

Filed Under: Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Boston Children's Hospital

Biologics & auto-injectors: How West Pharma designs for evolving trends in drug delivery

October 12, 2017 By Sarah Faulkner

West Pharmaceutical

If you’ve ever received a flu shot or taken insulin, you’ve probably used a device designed by West Pharmaceutical Services (NYSE:WST), according to VP & GM of biologics Graham Reynolds. “Probably most people have come in contact with West and they wouldn’t even know it,” he told Drug Delivery Business News. Over the 40 years he’s been […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, West Pharmaceutical Services

Convenience, compliance & control: How Insulet is changing insulin delivery tech

September 21, 2017 By Sarah Faulkner

Insulet Omnipod

Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other challenges that come with constantly wearing a pump. So when Petrovic was tapped to serve as chief commercial officer at Insulet (NSDQ:PODD) in […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Bigfoot Biomedical, Eli Lilly & Co., GlaxoSmithKline plc, Insulet, Medtronic, Ypsomed

Amgen shares fall after Q2 earnings reveal ‘bare’ pipeline

July 26, 2017 By Sarah Faulkner

Amgen

Shares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results. The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus

June 16, 2017 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Amgen, Novartis, sandoz

Alnylam, The Medicines Co., detail Phase III trial for RNA-based heart drug

April 26, 2017 By Sarah Faulkner

anatomical heart

The Medicines Co. (NSDQ:MDCO) and Alnylam Pharmaceuticals (NSDQ:ALNY) said today that they’ve reached a deal with the FDA over a Phase III trial for the companies’ RNA-based cholesterol-lowering drug, inclisiran. If approved, it would be the 1st RNA-interference therapy on the market. The drug is a part of a new group of drugs called PCSK9 […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Alnylam Pharmaceuticals, Amgen, Regeneron, The Medicines Co.

Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016

March 22, 2017 By Sarah Faulkner

Prescription drugs

Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Co., C.R. Bard, Catalent, Eli Lilly & Co., GlaxoSmithKline plc, Medtronic, Merck, Mylan, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

Pharma stocks fall on Trump’s proposal to cut NIH budget

March 16, 2017 By Sarah Faulkner

Pharma stocks fall on Trump's proposal to cut NIH budget

The Trump budget plan to slash more than 18% from the budget for the National Institutes of Health sent pharmaceutical stocks down today on Wall Street as investors reacted to the proposal. The budget proposal, released today, would cut the NIH budget by $5.8 billion, to $25.9 billion – an 18.3% cut. The proposal would also introduce […]

Filed Under: Featured, Policy, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Becton Dickinson, Biogen Idec, Boston Scientific, C.R. Bard, Gilead Sciences, johnsonandjohnson, Medtronic, Merck, Pfizer Inc.

Trump drug pricing tweet sends pharma stocks down

March 7, 2017 By Sarah Faulkner

Prescription drugs

Shares in Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Amgen (NSDQ:AMGN) fell slightly this morning after President Donald Trump tweeted that he was working on a “new system” to lower drug prices. “I am working on a new system where there will be competition in the Drug Industry,” he wrote. “Pricing for the American people will come way down!” […]

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., johnsonandjohnson, Marathon Pharmaceuticals, Merck, Pfizer Inc.

Amgen wins marketing authorization for Repatha single-dose delivery option

February 23, 2017 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) said today that the European Commission granted a change to the marketing authorization of its Repatha device, approving a single-dose delivery option. The pre-filled cartridge mini-doser is a hands-free device that is designed to provide 420 mg of Repatha (evolocumab) in a single injection for patients with cardiovascular disease. The company touted its […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS